

A lung cancer precision medicine trial

VOLUME 17 | SUMMER 2021

NEWSLETTER

WWW.LUNG-MAP.ORG

Lung-MAP at ASCO21 (and Beyond)

Lung-MAP researchers presented results from two sub-studies in poster sessions at the ASCO annual meeting in June. **Karen Reckamp, MD**, presented <u>toxicity data for S1800A</u>, a non-match sub-study, and **Jonathan Riess, MD**, presented <u>results from sub-study S1900A</u>.

Riess was also lead author on an editorial in the May 2021 issue of Clinical Lung Cancer: "Novel Clinical Trial Designs in Pursuit of Precision Oncology: LUNG-MAP as a Model." Christian Rolfo, MD, PhD, MBA, and David Gandara, MD, one of Lung-MAP's founding Pls, were coauthors.









Reckamp

Riess

Rolfo

Gandara

A Screening Choice: Previous FoundationOne CDx Results OR Tissue Submission?


Patients who previously had commercial FoundationOne CDx tissue testing done can now be screened for Lung-MAP sub-study assignment based on those results instead of submitting tissue. Results from a solid tumor FoundationOne CDx report done as early as September 1, 2019, can be reanalyzed by Foundation Medicine for Lung-MAP biomarker profiling.

You can start the reanalysis process using the SWOG Specimen Tracking System. A step-by-step guide is available.

This change means the informed consent document has also changed. It now includes several "OR" statements based on whether the patient is releasing tissue for testing or releasing previous results. Make sure your patients know which option they are consenting to.

Learn more on the <u>Lung-MAP training page</u>. You can also contact the Lung-MAP data coordinators at LUNGMAPquestion@crab.org.





LEARN MORE AT www.lung-map.org











A Look Ahead:

S1800D, a Lung-MAP non-match sub-study, is expected to activate by fall 2021. It will compare treatment with the combination of N-803 plus pembrolizumab to standard of care treatment for patients who have progressed on or after an anti-PD-1 or anti-PD-L1 therapy. The study was previewed at the spring 2021 SWOG group meeting, and a <u>recording of this presentation</u> is available (at the 43:25 timepoint).

As of 6/18/2021, the new LUNGMAP protocol has logged:

2065 screening registrations | **987** sub-study assignments | **290** sub-study registrations

TOP ACCRUING SITES*

| 1. UPMC Hillman Cancer Center | Pittsburgh, PA | 125 |
|-----------------------------------------------------------------------------------|-------------------|-----|
| 2. UNM Comprehensive Cancer Center | Albuquerque, NM | 39 |
| 3. Mercy Medical Center | Canton, OH | 37 |
| 4. Wilmot Cancer Institute | Rochester, NY | 33 |
| 5. Missouri Baptist Medical Center | St. Louis, MO | 30 |
| 6. Roswell Park Comprehensive Cancer Center | Buffalo, NY | 27 |
| 7. Markey Cancer Center | Lexington, KY | 24 |
| 7. Good Samaritan Hospital | Cincinnati, OH | 24 |
| 7. Stephenson Cancer Center | Oklahoma City, OK | 24 |
| 8. Essentia Health | Duluth, MN | 23 |
| 8. Virginia Cancer Institute | Richmond, VA | 23 |
| 9. Northside Hospital Cancer Institute | Atlanta, GA | 21 |
| 10. University of CA Davis Comprehensive Cancer Center | Sacramento. CA | 20 |
| 10. Veterans Affairs Connecticut Healthcare System – | West Haven, CT | 20 |
| 10. Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, IL | 20 |
| 10. Baystate Medical Center | Springfield, MA | 20 |
| 10. Sparrow Hospital | Lansing, MI | 20 |
| | | |

*As of 6/18/21

CONTACT US

Protocol & Regulatory Questionslgildner@swog.org or jbeeler@swog.org

Eligibility & Data Submission Questions LUNGMAPQuestion@crab.org

General Medical Questions LUNGMAP@swog.org

Central Monitoring Questions centralmonitorquestion@crab.org

Quality Assurance Auditing Questions qamail@swog.org

Funding Questions funding@swog.org

S1900E Study Chairs S1900EMedicalQuery@swog.org